Barr J, Kirkpatrick N, Dick A, Leonard L, Hawksworth G, Noble D W
Department of Anaesthesia, Aberdeen Royal Infirmary, Foresterhill.
Br J Anaesth. 1995 Dec;75(6):692-7. doi: 10.1093/bja/75.6.692.
We have measured peak plasma concentrations of lignocaine and bupivacaine after dual injection peribulbar block and investigated the influence of adrenaline and hyaluronidase. Twenty-four patients were allocated randomly to one of four groups: (I) local anaesthetic alone (lignocaine 10 mg ml-1-bupivacaine 3.75 mg ml-1); (II) local anaesthetic with adrenaline (5 micrograms ml-1); (III) local anaesthetic with hyaluronidase (75 iu ml-1); or (IV) local anaesthetic with adrenaline and hyaluronidase. Venous plasma concentrations of lignocaine and bupivacaine were measured in 24 patients using gas liquid chromatography before and at 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180, 300 and 540 min after completion of the peribulbar injections. Main outcome measures were analysed using two-way analysis of variance. All patients, with one exception, received 10 ml of the local anaesthetic mixture. Overall peak plasma concentrations varied from 230 to 1910 micrograms ml-1 for lignocaine and from 160 to 1090 micrograms ml-1 for bupivacaine. Adrenaline significantly reduced peak plasma concentrations of lignocaine to 57% (P = 0.001) and bupivacaine to 61% (P = 0.004) compared with the nonadrenaline groups. Hyaluronidase had no significant effect on peak plasma concentrations of lignocaine and bupivacaine, which were 90% (P = 0.34) and 100% (P = 0.84) of the non-hyaluronidase groups. The area under the plasma concentration-time curves to 300 min (AUC300) behaved similarly. There was a reduction in AUC300 for lignocaine (P = 0.005) and bupivacaine (P = 0.011) in the adrenaline groups compared with the non-adrenaline groups, in contrast with no significant effects of hyaluronidase on AUC300 for lignocaine (P = 0.14) or bupivacaine (P = 0.53) compared with the non-hyaluronidase groups.
我们测量了球周阻滞双注射后利多卡因和布比卡因的血浆峰值浓度,并研究了肾上腺素和透明质酸酶的影响。24例患者被随机分为四组之一:(I)仅用局部麻醉药(利多卡因10mg/ml - 布比卡因3.75mg/ml);(II)局部麻醉药加肾上腺素(5μg/ml);(III)局部麻醉药加透明质酸酶(75iu/ml);或(IV)局部麻醉药加肾上腺素和透明质酸酶。在球周注射完成前及注射后5、10、15、20、25、30、45、60、90、120、180、300和540分钟,使用气相色谱法测量24例患者静脉血浆中利多卡因和布比卡因的浓度。主要观察指标采用双向方差分析。除1例患者外,所有患者均接受10ml局部麻醉药混合液。利多卡因的总体血浆峰值浓度在230至1910μg/ml之间,布比卡因在160至1090μg/ml之间。与无肾上腺素组相比,肾上腺素显著降低了利多卡因的血浆峰值浓度至57%(P = 0.001),布比卡因至61%(P = 0.004)。透明质酸酶对利多卡因和布比卡因的血浆峰值浓度无显著影响,分别为无透明质酸酶组的90%(P = 0.34)和100%(P = 0.84)。血浆浓度 - 时间曲线下至300分钟的面积(AUC300)表现相似。与无肾上腺素组相比,肾上腺素组中利多卡因(P = 0.005)和布比卡因(P = 0.011)的AUC300降低,相反,与无透明质酸酶组相比,透明质酸酶对利多卡因(P = 0.14)或布比卡因(P = 0.53)的AUC300无显著影响。